PURPOSE. We aimed to evaluate if metformin improves diastolic function (DF) in non-diabetic patients with MetS. METHODS. A prospective, randomized, open-label, blinded-endpoint trial was conducted over 24 months. Fifty-four non-diabetic adults with MetS and DD (defined as mean e'<10.2cm/s ...
The drug does not cause hypoglycemia in nondiabetic patients and is effective in both obese and nonobese patients with non-insulin-dependent diabetes mellitus (NIDDM). The drug does not act through stimulation of endogenous insulin secretion. It seems to act at multiple sites, with a small ...
Despite the fact that its precise mechanism of action it is not completely elucidated, long-term treatment with this drug in monotherapy, improves glycaemic control and reduces cardiovascular mortality in overweight type 2 diabetic patients. Experimental evidence produced over the years suggests that ...
The article looks at the connection of metformin in left ventricular (LV) function of nondiabetic patients and mentions topics like the comparison between placebo and metformin on heart function and results revealing that metformin did cause changes on blood sugar levels nor enhanced LV function....
This explains that MET treatment has also been shown to induce regression of LV-hypertrophy and exert anti-oxidant effects even in non-diabetic patients37. Similarly, LV reverse remodeling has been observed in other drugs that activate AMPK such as SGLT2-inhibitors38. In non-HF subjects, MET ...
Charles MA, Morange P, Eschwege E, Andre P, Vague P, Juhan-Vague I: Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects: the BIGPRO1 Study. Biguanides and the Prevention of the Risk of Obesity. Diabetes Care. 1998, 21: 1967...
Additionally, this manuscript briefly reviews the thyroid stimulating hormone (TSH)-lowering properties in diabetic and non-diabetic patients, besides reviewing its actions on different types of cancers. Some of these actions may become approved indications for use of metformin following generation of ...
CONCLUSION: Metformin use is not associated with overall or subtype NHL risk among diabetic patients. IMPACT: NHLs are etiologically heterogeneous and larger scale studies are warranted to test the potential effect of metformin by NHL subtype. Copyright 2018, American Association for Cancer Research....
We excluded (1) patients < 50 years (n = 61,093); (2) patients diagnosed with dementia before the DM diagnosis (n = 924); (3) patients who had not used antidiabetic medications (n = 21,867); (4) patients receiving insulin treatment for > 3 months (n =...
Fig. 1: Elevated serum Lac-Phe in patients with T2D. a, Distribution of 33 non-diabetic (non-T2D), pre-diabetic (pre-T2D) and diabetic (T2D) participants in the Brigham and Women’s Hospital cohort study. b, Volcano plot comparing metabolomes of obese non-T2D (n = 11) and obese...